Mayo Clinic is not asking the US Supreme Court for an “exotic” application of Section 101, and the personalised medicine industry will be fine without patents like that owned by Prometheus, the company’s counsel told Managing IP on Thursday
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
A&O Shearman and Fish & Richardson invested in German talent, meanwhile, major firms have assembled for an on the merits case pitting KeeeX against OpenAI and Adobe